View Older Stories

Jun 1, 2026 02:09PM Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush

May 7, 2026 08:04AM Edgewise Therapeutics, Inc. (EWTX) Tops Q1 EPS by 3c

Mar 17, 2026 07:11AM Edgewise Therapeutics (EWTX) PT Raised to $45 at JPMorgan on 2026 Catalysts

Mar 10, 2026 09:49AM Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX): "we expect investor interest to grow"

Mar 10, 2026 08:41AM Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX) following MESA OLE update

Mar 10, 2026 07:02AM Edgewise reports sevasemten stabilized function in Becker dystrophy study

Feb 26, 2026 04:02PM Edgewise Therapeutics (EWTX) PT Raised to $45 at Evercore ISI

Feb 26, 2026 02:31PM Raymond James: 'we continue to see a highly attractive long-term risk/reward skew for EWTX'

Feb 26, 2026 09:50AM Edgewise Therapeutics (EWTX) PT Raised to $25 at Stifel

Feb 26, 2026 08:06AM Edgewise Therapeutics, Inc. (EWTX) Misses Q4 EPS by 3c

Feb 9, 2026 09:00AM Piper Sandler: 'We see substantial upside potential for Edgewise Therapeutics (EWTX)'

Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note

Nov 6, 2025 04:04PM Edgewise Therapeutics (EWTX) PT Lowered to $32 at Wedbush

Nov 6, 2025 08:42AM Edgewise Therapeutics, Inc. (EWTX) Tops Q3 EPS by 1c

Nov 3, 2025 09:25AM Truist Reiterates Buy Rating on Edgewise Therapeutics (EWTX)

Sep 24, 2025 04:18PM Goldman Sachs Starts Edgewise Therapeutics (EWTX) at Neutral

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 20, 2025 08:26AM JPMorgan Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)

Aug 8, 2025 08:43AM Edgewise Therapeutics (EWTX) PT Raised to $49 at RBC Capital

Aug 7, 2025 10:44AM Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX)

Aug 7, 2025 08:02AM Edgewise Therapeutics, Inc. (EWTX) Tops Q2 EPS by 8c

Jul 29, 2025 04:25PM Raymond James Starts Edgewise Therapeutics (EWTX) at Strong Buy

Jun 30, 2025 06:05AM H.C. Wainwright Starts Edgewise Therapeutics (EWTX) at Buy

Jun 27, 2025 10:36AM RBC Capital on Edgewise Therapeutics (EWTX): ' We Would Be Buyers on Weakness'

Jun 26, 2025 10:32AM Stifel Reiterates Hold Rating on Edgewise Therapeutics (EWTX)

Jun 26, 2025 06:00AM Edgewise Therapeutics Inc. (EWTX) Reports Positive Results on Sevasemten Program

Jun 11, 2025 08:35AM Piper Sandler Sees 'Meaningful Upside Opportunities' for Edgewise Therapeutics (EWTX)

Jun 5, 2025 08:53AM RBC Capital Reiterates Outperform Rating on Edgewise Therapeutics (EWTX)

May 8, 2025 08:05AM Edgewise Therapeutics, Inc. (EWTX) Reports In-Line Q1 EPS

Apr 3, 2025 08:52AM RBC Capital on Edgewise Therapeutics (EWTX): 'We See Downside Move As A Buying Opportunity'; PT Lowered

Apr 2, 2025 03:04PM Edgewise Therapeutics Inc. (EWTX) April 20, April 21, April 22 and May 15 puts active as share price down 21%

Apr 2, 2025 01:34PM Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), PT $50

Apr 2, 2025 09:22AM Morgan Stanley Reiterates Overweight Rating on Cytokinetics (CYTK)

Apr 2, 2025 06:23AM Edgewise Therapeutics Inc. (EWTX) Announces Pricing of $200M Underwritten Offering of Common Stock

Apr 2, 2025 06:00AM Edgewise Therapeutics Inc. (EWTX) Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy

Mar 21, 2025 10:23AM Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), PT $50

Mar 10, 2025 09:44AM Piper Sandler: 'We Remain Bullish on Edgewise Therapeutics (EWTX) and See Compelling Buying Opportunity'

Mar 7, 2025 07:10AM Scotiabank Starts Edgewise Therapeutics (EWTX) at Sector Outperform

Mar 3, 2025 08:02AM Edgewise Therapeutics, Inc. (EWTX) Reports In-Line Q4 EPS

Feb 20, 2025 03:02PM Edgewise Therapeutics Inc. (EWTX) spreader of 3K contracts of March 12.50 puts against 3K contracts of April 22 puts as share price up 4.9%

Feb 14, 2025 09:14AM Edgewise Therapeutics (EWTX) PT Raised to $45 at JPMorgan

Jan 22, 2025 08:08AM Edgewise Therapeutics (EWTX) Strengthens Leadership Team to Support Late-Stage Clinical Development

Jan 21, 2025 04:08PM Stifel Starts Edgewise Therapeutics (EWTX) at Hold

Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Dec 16, 2024 08:49AM Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX) Following Positive Ph2 Data

Dec 16, 2024 06:05AM Edgewise Therapeutics Inc. (EWTX) Reports Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten

Dec 5, 2024 02:32PM Edgewise Therapeutics Inc. (EWTX) Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

Dec 5, 2024 01:02PM Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'

Nov 30, 2024 10:00PM JPMorgan is out with its 2025 outlook for biotech stocks

View Older Stories